2000-19年183个国家按癌症类型、性别、WHO区域和世界银行收入水平划分的过早死亡率趋势:一项回顾性、横断面、基于人群的研究
该回顾性横断面人群研究利用WHO全球卫生估计数据,分析2000-19年183个国家全癌种及13种特定癌症的过早死亡率趋势。结果显示138个国家(75%)过早死亡率下降,但仅8个国家(4%)可能达到可持续发展目标3.4。高收入国家在乳腺癌和结直肠癌等早诊癌症的过早死亡率下降幅度大于低收入国家。
要点
- 2000-19年183个国家中138个(75%)全癌种过早死亡率下降,但仅8个(4%)可能达到SDG 3.4目标。
- 高收入国家乳腺癌过早死亡率下降比例为48/54(89%),低收入国家为7/29(24%)。
- 高收入国家结直肠癌过早死亡率下降比例为45/54(83%),低收入国家为4/29(14%)。
核心结论
- 高收入国家全癌种及特定癌种的过早死亡率下降幅度大于中低收入和低收入国家,但大多数国家不会达到SDG 3.4目标。
- 作者认为,对预防、早期检测和治疗的投入可能加速过早死亡率的下降。
研究设计与样本
- 回顾性、横断面、基于人群的研究,使用WHO全球卫生估计数据,分析2000-19年183个国家全癌种及13种特定癌症的过早死亡率趋势。
- 按WHO区域、世界银行收入水平和性别分层,计算30-69岁人群的过早死亡风险,采用标准生命表方法独立于其他竞争死因。
- 主要目标为计算2000-19年过早死亡率的平均年变化率,次要目标评估该年变化率是否足以在2030年达到SDG 3.4目标。
主要发现
- 2000-19年,183个国家中138个(75%)全癌种过早死亡率下降,覆盖所有世界银行收入水平和WHO区域。
- 仅8个(4%)国家可能达到全癌种合并的SDG 3.4目标。
- 高收入国家乳腺癌过早死亡率下降比例为48/54(89%),低收入国家为7/29(24%);结直肠癌高收入国家为45/54(83%),低收入国家为4/29(14%)。
- 宫颈癌过早死亡率下降的国家数量:高收入国家50/54(93%),低收入国家26/29(90%)。
- 过早死亡率的性别差异因WHO区域、世界银行收入组和癌症类型而异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer is a leading cause of mortality worldwide. By 2040, over 30 million new cancers are predicted, with the greatest cancer burden in low-income countries. In 2015, the UN passed the Sustainable Development Goal 3.4 (SDG 3.4) to tackle the rising burden of non-communicable diseases, which calls for a reduction by a third in premature mortality from non-communicable diseases, including cancer, by 2030. However, there is a paucity of data on premature mortality rates by cancer type. In this study, we examine annual rates of change for cancer-specific premature mortality and classify whether countries are on track to reach SDG 3.4 targets. METHODS: This is a retrospective, cross-sectional, population-based study investigating premature mortality trends from 2000-19 using the WHO Global Health Estimates data. All cancers combined and thirteen individual cancers in 183 countries were examined by WHO region, World Bank income level, and sex. The risk of premature mortality was calculated for ages 30-69 years, independent of other competing causes of death, using standard life table methods. The primary objective was to compute average annual rate of change in premature mortality from 2000 to 2019. Secondary objectives assessed whether this annual rate of change would be sufficient to reach SDG 3.4. targets for premature mortality by 2030. FINDINGS: This study was conducted using data retrieved for the years 2000-19. Premature mortality rates decreased in 138 (75%) of 183 countries across all World Bank income levels and WHO regions, however only eight (4%) countries are likely to meet the SDG 3.4 targets for all cancers combined. Cancers where early detection strategies exist, such as breast and colorectal cancer, have higher declining premature mortality rates in high-income countries (breast cancer 48 [89%] of 54 and colorectal cancer 45 [83%]) than in low-income countries (seven [24%] of 29 and four [14%]). Cancers with primary prevention programmes, such as cervical cancer, have more countries with declining premature mortality rates (high-income countries 50 [93%] of 54 and low-income countries 26 [90%] of 29). Sex-related disparities in premature mortality rates vary across WHO regions, World Bank income groups, and by cancer type. INTERPRETATION: There is a greater reduction in premature mortality for all cancers combined and for individual cancer types in high-income countries compared with lower-middle-income and low-income countries. However, most countries will not reach the SDG 3.4 target. Cancers with early detection strategies in place, such as breast and colorectal cancers, are performing poorly in premature mortality compared with cancers with primary prevention measures, such as cervical cancer. Investments toward prevention, early detection, and treatment can potentially accelerate declines in premature mortality. FUNDING: WHO.
引用
- Murthy SS, Trapani D, Cao B, et al. Premature mortality trends in 183 countries by cancer type, sex, WHO region, and World Bank income level in 2000-19: a retrospective, cross-sectional, population-based study. Lancet Oncol. 2024. PMID: 38964357. doi:10.1016/S1470-2045(24)00274-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。